Literature DB >> 7548274

Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth.

P L Lollini1, C De Giovanni, L Landuzzi, G Nicoletti, F Frabetti, F Cavallo, M Giovarelli, G Forni, A Modica, A Modesti.   

Abstract

The mouse mammary carcinoma TS/A, of BALB/c (H-2d) origin, was transfected with the murine interferon-gamma (IFN-gamma) gene (Int. J. Cancer 55: 320, 1993). We used IFN-gamma transfectants as recipients for a second round of transfections with murine allogeneic class I histocompatibility (H-2b) genes that are modulated by IFN. Transfectants with either gene alone, as well as parent TS/A cells (TS/A-pc), were used as controls. Only double transfectants expressed high levels of the allogeneic H-2b genes, while in H-2b single transfectants the expression was very low (but was induced by treatment with exogenous IFN-gamma). The tumorigenic potential of IFN-gamma or H-2b single transfectants was reduced in comparison to TS/A-pc. IFN-gamma+H-2Kb double transfectants were almost nontumorigenic, while IFN-gamma+H-2Db clones gave rise to tumors in about one-half of mice. The experimental metastatic ability of all IFN-gamma+H-2b double transfectants was very low. IFN-gamma single transfectants were known to induce a strong macrophage response in the host. The expression of allogeneic H-2 antigens added a T-lymphocyte-mediated response that accounted for the lower tumorigenicity of double transfectants. These results show that it is possible to steer the immune response evoked by tumor cells for therapeutic purposes. Moreover, the high H-2 expression obtained in IFN-gamma+H-2b double transfectants suggests that single IFN-gamma transfectants are ideal recipients for all IFN-sensitive genes. This approach can be used also for other general-purpose inducers of gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548274     DOI: 10.1089/hum.1995.6.6-743

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  4 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 2.  Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?

Authors:  M P Colombo; M Rodolfo
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

3.  Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells.

Authors:  P Nanni; C De Giovanni; L Landuzzi; G Nicoletti; F Frabetti; I Rossi; F Cavallo; M Giovarelli; G Forni; P L Lollini
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

Review 4.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Authors:  Carla De Giovanni; Giordano Nicoletti; Lorena Landuzzi; Arianna Palladini; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.